Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy

A method for treating a patient who is suffering from epilepsy with co-administering a therapeutically effective amount of (i) [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-ylethyl] carbamate (cenobamate) or a pharmaceutically acceptable salt thereof and (ii) one or two antiepileptic drugs, said method comprising:

• modifying the therapeutically effective amount of the antiepileptic drug to adjust AUC of the antiepileptic drug obtained after the co-administration having at least 5% difference to the level of AUC obtained after the administration of antiepileptic drug to the patient without cenobamate or a pharmaceutically acceptable salt thereof,
• wherein the antiepileptic drug is selected from the group consisting of phenobarbital and phenytoin, and
• wherein the therapeutically effective amount of cenobamate is achieved by the following titration method:
• (1) administering cenobamate to the patient about 12.5 mg once daily for about two weeks;
• (2) then administering cenobamate to the patient about 25 mg once daily for two weeks;
• (3) then administering cenobamate to the patient about 50 mg once daily for about two weeks;
• and
• (4) then increasing the dose in about bi-weekly increments by no more than about 50 mg once daily to a therapeutically effective amount.